APLS earnings: a negative outcome, -9.1%

On August 1, 2024, Apellis Pharmaceuticals, Inc. reached its earnings. The result was a negative outcome, and the stock moved -9.1% in the window around the event. It had already run +12.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.